Archive - APTM

Bayer is hoping sevabertinib will be the next alectinib

22 hrs ago • Sal Haque

February 2026

What is Alumis's Envudeucitinib valuation?

Alumis's shares soared after Envudeucitinib was successful in a Phase 3 trial in psoriasis but it enters a competitive market. Will the drug be a…

Feb 2 • Sal Haque

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts